Male hypogonadism and civilization diseases
Authors:
Lubomír Stárka
Authors‘ workplace:
Endokrinologický ústav, Praha
Published in:
Čas. Lék. čes. 2012; 151: 69-72
Category:
Review Article
Overview
Age dependant decrease of testosterone levels leads in many men to hypogonadism called as late-onset hypogonadism. Morbidity and mortality of men with subnormal testosterone levels is higher than that of men sufficiently supplied with androgens. Cardiovascular diseases, obesity or diabetes take often part in these events. Low testosterone level is risk factor for these diseases. However, it is until now not clear whether testosterone deficiency is a cause or consequence of atherosclerosis or metabolic syndrome. A handful of symptoms and metabolic parameters present in hypogonadal men can be ameliorated by testosterone supplementation. Testosterone has a beneficial effect on cardiovascular risk factors, but it is not clear whether it can reduce mortality.
Key words:
testosterone, cardiovascular diseases, obesity, metabolic syndrome, diabetes mellitus.
Sources
1. Blahoš J, Zamrazil V. Endokrinologie – interdisciplinární obor. Praha: Triton 2009.
2. Andersson AM, Jensen TK, Juul A, Petersen JH, JŅrgensen T, Skakkebaek NE. Secular decline in male testosterone and sex hormone binding globulin serum levels in Danish population surveys. J Clin Endocrinol Metab 2007; 92(12): 4696–4705.
3. Tajar A, Forti G, O‘Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European Male Ageing Study. J Clin Endocrinol Metab 2010; 95: 1810–1818.
4. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006; 91: 4335–4343.
5. Haring R, Ernst F, Schurmann C, Homuth G, Völker U, Völzke H, Nauck M, Wallaschofski H. The androgen receptor CAG repeat polymorphism as a risk factor of low serum testosterone and its cardiometabolic effects in men. Int J Androl. Sep 27. doi: 10.1111/j.1365-2605.2011.01220.x.
6. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91(6): 1995–2010.
7. Bhasin S, Cunnigham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori V. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society Clinical practice guideline. J Clin Endocrinol Metab 2010; 95(6): 2536–2559.
8. Jones TH. Testosterone deficiency: a risk actor for cardiovascular disease? Trends Endocrinol Metab 2010; 21: 496–503.
9. Vrbíková J, Stanická S, Vondra K, Zajíčková K, Stárka L. Insulin resistance in endocrine disorders. In: Insulin Resistance New Research. Ed. E.B. Yao, Nova Sci. Publ. Inc, 2009; 1–47.
10. Webb CM, Collins P. Testosterone and coronary artery disease in men. Maturitas 2010; 67: 15–19.
11. Laughlin GA, Barret-Connor E, Bergström J. Low serum testosterone and mortality in older men. J Clin Endocrin Metab 2008; 9: 68–75.
12. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellström D, Ohlsson C. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 2009; 94(7): 2482–2488.
13. Sievers C, Klotsche J, Pieper L, Schneider HJ, März W, Wittchen HU, Stalla GK, Mantzoros C. Low testosterone leevels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients. Eur J Endocrinol 2010; 163: 699–708.
14. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96(10): 3007–3019.
15. Nettleship JE, Jones RD. Channer KS, Jones TH. Testosterone and coronary artery disease. Front Horm Res 2009; 37: 91–107.
16. Yeap BB, Chubb SA, Hyde Z, Jamrozik K, Hankey GJ, Flicker L, Norman PE. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men. The Health In Men Study. Eur J Endocrinol 2009; 161: 591–598.
17. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011; 97(11): 870–875.
18. Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K. Long-term benefits of testosterone replacement therapy on angina treshold and atheroma in men. Eur J Endocrinol 2009; 161: 443–449.
19. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. Effect of long-acting testostereone treatment on functional exercise capacity, skeletal muscle performace, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. A double-blind, placebo-controlled, randomised study. J Am Coll Cardiol 2009; 54: 919–927.
20. Stanworth RD, Jones TH. Testosterone in obezity, metabolic syndrome and type 2 diabetes. Front Horm Res. 2009; 37: 74–90.
21. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone binding globulin, total testosterone, and symptomatic androgen deficiency are associated with the decelopment of the metabolic syndrome, in no-obese men. J Clin Endocrinol Metab 2006; 91: 843–850.
22. Dandona P, Dhindsa S. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 2011; 96: 2643–2651.
23. Kubíček V. Racionalni substitučni terapie androgeny pro muže. Andrologie 2000; 1: 2–10.
24. Miner M, Canty DJ, Shabsigh R. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices. Postgrad Med 2008; 120: 130–153.
25. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuqerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori V. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95(6): 2560–2575.
26. Basaria S, Coviello AD, Travison T , Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ullor J, Zhang A, Choong K, Laksman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appelman E, Aggarwal S, Bhasin g, Hede-Brierley L, Bhatia A, Collins L, LaBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. N Engl J Med 2010; 363(2): 109–122.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Prevalence of thrombophilic mutations of FV Leiden, prothrombin G20210A and PAI-1 4G/5G and their combinations in a group of 1,450 healthy middle-aged individuals in the Prague and Central Bohemian regions (results of FRET real-time PCR assay)
- Relapsing polychondritis
- Male hypogonadism and civilization diseases
- Morphology and etiopathogenesis of the abdominal aortic aneurysm